Christina Miller
Primary Care · Deridder, LANPI 1023789328
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.
Across 51 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$151
- Novo Nordisk$100
- Axsome Therapeutics, Inc.$87
- Astellas Pharma US Inc$81
- Teva Pharmaceuticals USA, Inc.$63
- Sanofi$62
- plus $443 from 15 others
What the payments were for
- Food & beverage$988100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$988 in reported general payments places this provider in the 60th percentile of 106 primary care providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $17,794 |
| JardianceEmpagliflozin | 12 | $13,825 |
| FarxigaDapagliflozin Propanediol | 16 | $13,194 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,508 |
| MyrbetriqMirabegron | 15 | $7,329 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,346 |
| SynthroidLevothyroxine Sodium | 21 | $1,310 |
| Atorvastatin Calcium | 52 | $649 |
| Megestrol Acetate | 11 | $640 |
| Levothyroxine Sodium | 25 | $580 |
| Pregabalin | 22 | $498 |
| Metoprolol Succinate | 25 | $357 |
| Sucralfate | 19 | $327 |
| Pantoprazole Sodium | 37 | $301 |
| Metformin Hcl | 27 | $256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $22 | $13,19416 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $7,32915 claims |
| AbbVieSynthroid | $151 | $1,31021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 106 primary care providers in Louisiana.
Other primary care in Deridder
- Wendy TaylorShreveport$15K
- Jodi BurasCovington$14K
- Mia Schexnayder-DavisNew Orleans$10K
- Lourdes TorresMonroe$8K
- Danielle WebsterPrairieville$8K
- Alle NorrisCovington$6K
- Ariel GrahamRayville$6K
- Eleisa FloydHouma$6K
- Emily FusilierBaton Rouge$5K
- Angela ParettiCovington$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.